Lancet Neurology

Article	Citations
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	1483
Anti-CD19 CAR T cells for refractory myasthenia gravis	1165
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	1038
Lessons and future directions for GBA1-targeting therapies	1035
Correction to Lancet Neurol 2025; 24: 850–65	881
Increasing diversity in dementia research	621
Traumatic brain injury research: homogenising heterogeneity	611
Correction to Lancet Neurol 2022; 21: 42–52	560
Correction to Lancet Neurol 2024; 23: 168–77	550
Correction to Lancet Neurol 2021; 20: 448–59	522
Correction to Lancet Neurol 2025; 24: 850–65	464
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	446
Implications of the KIWE trial for low-income and lower-middle-income countries	435
Global burden of stroke: dynamic estimates to inform action	398
A biological classification of Huntington's disease: the Integrated Staging System	343
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease	327
The relevance of social and commercial determinants for neurological health	308
The predictive value and clinical use of the neurological pupillary index – Authors' reply	304
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	295
Resolution of expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study	287
Multidisciplinary care for amyotrophic lateral sclerosis	276
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	271
Dementia diagnosis in the anti-amyloid era	246
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	238
Correction to Lancet Neurol 2020; 19: 391–401	236

RAB32 mutation in Parkinson's disease	233
Surrogate endpoints for progressive multifocal leukoencephalopathy	228
Parkinson's disease is a recognisable and useful diagnostic entity	228
Gene therapy for X-linked myotubular myopathy: the challenges	217
Diana Cejas	201
Guiding the future of neurology: our peer-reviewers in 2025	186
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	185
Considering the neurological health needs of LGBTQIA people	180
Elia M Pestana Knight	178
Albert Kwaku Akpalu	173
Beyond the modular brain	173
A chilly tale of dementia	166
A nasal CGRP receptor antagonist for acute migraine therapy	162
A study in healing the wounds of trauma	155
Trials in intracerebral haemorrhage: a path to success?	147
Delving into the human mind	145
Epilepsy syndromes: an essential piece of the puzzle	143
Amyotrophic lateral sclerosis from genotoxins alone?	143
2025 for neuromuscular diseases: a year of multiple advances	140
Correction to Lancet Neurol 2022; 21: 284–94	139
Correction to Lancet Neurol 2023; 22: 812–25	138
The prescription of valproate: risk of harm	132
Aspiring to restore arm and hand function after stroke	130
From stroke awareness to stroke action awareness	130
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	129
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	128
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment	125
A sensitive portrayal of a controversial condition	124
Global burden of headache disorders: innovations, disparities, and priorities for action	122
Miratul Muqit: leading an alliance to decode Parkinson's disease	120
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	119
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	116
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	115
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	115
Functional or hysterical?	115
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	112
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	112
Cognitive function in people with functional seizures	112
Correction to Lancet Neurol 2024; 23: 110–22	111
Correction to Lancet Neurol 2022; 21: 620–31	111
Multiple sclerosis in 2022: old players, new insights	110
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	107
New results for risdiplam in spinal muscular atrophy	106
Responsible innovation in neurology	103
Expansion of stenting indications in the USA	103
Jessica Ailani	102
Exploring immunomodulation with azathioprine in Parkinson's disease	100
α-synuclein seed amplification and its uses in Parkinson's disease	99
A proposal for equity neuroscience	98
Rethinking AI trials in brain health	96

Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	96
Changing multiple-sclerosis-induced thoughts and behaviours	95
Learning to be an adult with a disability	92
Supporting young carers across neurological disorders	91
Neurological infections in 2023: surveillance and prevention	90
Thank you to The Lancet Neurology's peer reviewers in 2025	89
Major advances in Parkinson's disease over the past two decades and future research directions	86
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	84
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	84
Revisiting candesartan: new evidence for an old option in migraine prevention	84
Global burden of meningitis: progress, gaps, and priorities	82
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	81
Detection of awareness after brain injury: time for change	80
ELEVATEd hope for patients after migraine treatment failure	80
Improving thrombolysis efficiency for acute ischaemic stroke	80
Pragmatic solutions for the global burden of stroke	79
A call for optimal oral care in patients with ALS	78
Monitoring brainwaves while gallery visitors view artworks	77
Neuroprotection in acute ischaemic stroke: reasons for optimism?	77
Expanding the spectrum of type 1 IFN neuroinflammation	75
Blocking inhibitors of axon growth after spinal cord injury	75
Eugenia Martínez	75
Sleeping matters	74
Your After-Visit Summary—May 29, 2042	74
Bastiaan Bloem: power against Parkinson's disease	72
Headache research in 2023: advancing therapy and technology	71
Consciousness contextualised	69
Living with dementia: seeing the world and adapting to it	68
Epilepsy research in 2022: clinical advances	66
The global challenge of hypertension	66
Correction to Lancet Neurol 2024; 23: 961–62	65
Andrea Schneider	65
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	64
Targeting auto-antibodies for CIDP: hope and questions	64
The AfrAbia+plus Parkinson's Disease Genomic Consortium	64
Siddharth Srivastava	64
Thrombolysis before endovascular treatment of tandem lesions	64
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	63
Questions about the brain at Edinburgh Festival Fringe	63
Caution on the use of α2δ-ligands in neuropathic pain	62
Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023	61
Neurorehabilitation as a cornerstone of recovery	60
Diagnosis and treatment of orthostatic hypotension	60
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	60
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	59
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	59
Highlights in traumatic brain injury research in 2024	58
Correction to Lancet Neurol 2024; 23: 344–81	58
The torment of needing to know for sure	57
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	57
Angela Dos Santos	56
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	56
Correction to Lancet Neurol 2024; 23: 465–76	56
Neurosurgical lesioning for Tourette syndrome – Authors' reply	55
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	55
NfL is ready for translation into paediatrics	53
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	53
Thank you to The Lancet Neurology's peer reviewers in 2023	53
Advances in amyotrophic lateral sclerosis research in 2022	52
No area of stroke research should be left behind	51
Over a decade of MR-guided focused ultrasound	51
The bases of remembrance	50
Major advances in sleep neurology: 2002–22	49
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	49
The cultural history of dementia	49
A brain design for life	49
Early atrial fibrillation rhythm control after stroke	49
Geoffrey Manley: TBI guy	49
Carlayne Jackson: leading the American Academy of Neurology	49
Charles Sherrington's apparatus	48
Further support for rituximab in relapsing multiple sclerosis	48
Laquinimod, Huntington's disease, and disease modification	47
Biomedical research must change as the climate does	46
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	46
Digital mobility measures to predict Parkinson's disease	46
Charles Bell's Renaissance inspiration	43
Targeting exercise, energy, or both in Friedreich's ataxia	43
Essential medicines for neurological disorders: updates, rejections, and the road ahead	42
For a dementia diagnosis, clinical acumen must precede biomarkers	42
The optimisation of migraine prevention: an urgent need	42

Therapies for myasthenia gravis: FcRn inhibition and beyond	41
Changing the landscape of neurological education	41
Improving epilepsy diagnosis across the lifespan: approaches and innovations	41
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	39
The complex pathway between amyloid β and cognition: implications for therapy	38
Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings	38
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	38
Sleep research in 2023: beyond the bare necessities	37
Nanna Brix Finnerup: integrity and openness to alternatives	36
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	36
Acute-onset axonal neuropathy following infection in children with biallelic RCC1 variants: a case series	36
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	36
Maria Trojano: advocate for real-world multiple sclerosis studies	35
Friston's theory of everything	35
Helping to bring the crisis home	35
Blue as an orange	35
Video games for people with neurological disorders	35
Revisiting levodopa for advanced Parkinson's disease	34
Neuroscience research in 2024: advances in blood biomarkers and brain omics	34
The prescription of valproate: risk of harm	34
Sleep matters in anti-LGI1 encephalitis	34
Abandon the NAC in α-synuclein	33
Time to get serious about the Global Action Plan on dementia	33
Nitrous oxide and its neurological harms	33
Global burden of meningitis and implications for strategy	32
Correction to Lancet Neurol 2025; 24: 880–92	32
Correction to Lancet Neurol 2025; 24: 969–75	32
Brain amyloid on the way to dementia prevention	32
Correction to Lancet Neurol 2025; 24: 413–28	32
RAB32 mutation in Parkinson's disease	32
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD	31
Correction to Lancet Neurol 2021; 20: 615–26	31
Globally advancing neurological education in headache	31
Lifestyle interventions for Parkinson's disease	31
Correction to Lancet Neurol 2023; 22: 209–17	31
Advances in diagnosis, classification, and management of pain in Parkinson's disease	30
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	30
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	30
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	30
Correction to Lancet Neurol 2024; 23: 344–81	29
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	29
Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications	29
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	28
Addressing neurological burden in the Americas	28
Blood pressure reduction and reperfusion therapy	28
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	28
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	27
A disease-specific therapy in facioscapulohumeral muscular dystrophy	27
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	27
A neurotransmitter with a fascinating story	27
The hidden unity of the mind	27
William Harvey, neurologist?	27
Cerebral amyloid angiopathy criteria: the next generation	26
Innovation in the prevention of neurological diseases	26
Treatment of acute subdural haematoma – Authors' reply	25
Fetal exposure to antiseizure medications: reassurance and concerns	25
Neuropsychiatry on screen	24
Vittorio Marchi's staining	24
With thanks to our peer reviewers in 2022	24
Treatment of asymptomatic carotid stenosis in SPACE-2	24
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	23
CGRP blockade and cluster headache: another step forward	23
Correction to Lancet Neurol 2019; 18: 748–59	22
Carotid revascularisation for carotid stenosis	22
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	22
Neurology cannot be embedded in non-communicable disease agendas	22
Time to end the stigma of epilepsy	22
Krithi Irmady	22
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	21
Differential diagnosis of suspected multiple sclerosis: global health considerations	21
Chronic effects of inflammation on tauopathies	21
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	21
Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023	21
Amyotrophic lateral sclerosis: a lesson in translation	21
Carpal tunnel syndrome: updated evidence and new questions	21
The Stimming Pool: an autistic production	21
Transforming amyotrophic lateral sclerosis into a liveable disease	20
Changing views of disability	20
Elucidating a new path of CSF transport in the CNS	20
Mar Tintoré, Mar Mediterráneo	19
Cerebral cavernous malformations: to operate or not?	19
Takeshi Iwatsubo: a pioneer in Alzheimer's disease research	18
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial	18
A multipronged approach to advancing palliative care for people with intellectual disabilities	18
Amyloid β, γ-secretase, and familial Alzheimer's disease	18
Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease	18
Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis	17
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study	17
Safety and effectiveness of the Walk ‘n Watch structured, progressive exercise protocol delivered by physical therapists for inpatient stroke rehabilitation in Canada: a phase 3, multisite, pragmatic,	17
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, pha	17
Sleep and sleep disorders in people with Parkinson's disease	17
Towards functional improvement of motor disorders associated with cerebral palsy	17
Intracranial pressure monitoring in adult patients with traumatic brain injury: challenges and innovations	16
Targeting C9orf72 in people with ALS	16
Nosferatu and the cinematic unglory of hysteria	16